Assenagon Asset Management S.A. Lowers Stake in Amicus Therapeutics, Inc. $FOLD

Assenagon Asset Management S.A. cut its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 47.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,848,454 shares of the biopharmaceutical company’s stock after selling 1,685,400 shares during the period. Assenagon Asset Management S.A. owned about 0.60% of Amicus Therapeutics worth $14,566,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Norges Bank purchased a new position in shares of Amicus Therapeutics during the second quarter worth approximately $18,540,000. Capital Fund Management S.A. boosted its stake in shares of Amicus Therapeutics by 408.8% in the 1st quarter. Capital Fund Management S.A. now owns 312,561 shares of the biopharmaceutical company’s stock valued at $2,550,000 after purchasing an additional 251,134 shares in the last quarter. Jump Financial LLC grew its holdings in shares of Amicus Therapeutics by 246.3% during the 2nd quarter. Jump Financial LLC now owns 1,406,563 shares of the biopharmaceutical company’s stock valued at $8,060,000 after purchasing an additional 1,000,395 shares during the last quarter. Advantage Alpha Capital Partners LP purchased a new position in Amicus Therapeutics in the 2nd quarter worth $201,000. Finally, Redmile Group LLC raised its position in Amicus Therapeutics by 35.1% in the 1st quarter. Redmile Group LLC now owns 9,533,669 shares of the biopharmaceutical company’s stock worth $77,795,000 after purchasing an additional 2,478,779 shares during the period.

Insider Transactions at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 77,926 shares of Amicus Therapeutics stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $10.86, for a total transaction of $846,276.36. Following the sale, the chief executive officer directly owned 1,129,782 shares in the company, valued at $12,269,432.52. The trade was a 6.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Ellen Rosenberg sold 23,621 shares of the company’s stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $10.00, for a total value of $236,210.00. Following the completion of the sale, the insider directly owned 507,710 shares in the company, valued at approximately $5,077,100. The trade was a 4.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 319,808 shares of company stock valued at $3,293,653. Insiders own 2.20% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on FOLD. Zacks Research upgraded shares of Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research note on Friday. The Goldman Sachs Group raised their price target on Amicus Therapeutics from $9.00 to $11.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 5th. Wall Street Zen raised Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, JPMorgan Chase & Co. boosted their price objective on Amicus Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Amicus Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $16.36.

Amicus Therapeutics Price Performance

Shares of Amicus Therapeutics stock opened at $14.20 on Friday. The business has a 50 day moving average of $9.48 and a 200 day moving average of $7.82. Amicus Therapeutics, Inc. has a 52 week low of $5.51 and a 52 week high of $14.36. The company has a market cap of $4.38 billion, a PE ratio of -354.81 and a beta of 0.46. The company has a quick ratio of 2.09, a current ratio of 2.99 and a debt-to-equity ratio of 1.70.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.05. Amicus Therapeutics had a negative net margin of 2.35% and a positive return on equity of 6.95%. The firm had revenue of $169.06 million for the quarter, compared to analyst estimates of $165.24 million. During the same quarter in the previous year, the firm posted $0.10 EPS. The company’s revenue for the quarter was up 19.5% compared to the same quarter last year. As a group, equities research analysts forecast that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current year.

Amicus Therapeutics News Roundup

Here are the key news stories impacting Amicus Therapeutics this week:

• Positive Sentiment: BioMarin to acquire Amicus for ~$4.8B ($14.50 per share), citing complementary marketed products (Galafold, Pombiliti + Opfolda), $599M of recent revenue and expectations the deal will be accretive to non‑GAAP EPS within 12 months — this provides a clear exit price and strategic rationale that pushed the stock up. Article Title
• Positive Sentiment: BioMarin’s press release emphasizes revenue upside from bringing Amicus products into BioMarin’s global footprint and resolving pending patent litigation on Galafold — details that support the acquisition valuation and near-term revenue accretion view. Article Title
• Neutral Sentiment: Trading was temporarily halted pre-market for “news pending,” then resumed around the acquisition announcement — a procedural sign the market treated the item as material. (Trading halt noted in market alerts.)
• Neutral Sentiment: Cantor Fitzgerald reaffirmed a “neutral” rating with a $14.50 price target (roughly in line with the deal price), and Needham reiterated a “hold” — analyst stances imply limited upside beyond the announced offer price absent a competing bidder. Article Title
• Negative Sentiment: Two investor‑rights firms (Halper Sadeh LLC and The Ademi Firm) announced investigations into whether the $14.50 per‑share sale is fair to Amicus shareholders — litigation or proxy fights could delay closing, pressure timing, or open the door to a higher bid/renegotiation, increasing deal execution risk. Article Title
• Negative Sentiment: Insider selling disclosures (including recent sales by the CEO and another officer) surfaced in filings earlier this week — while not unusual, these sales add a note of caution for some investors evaluating management alignment ahead of the deal. Article Title

Amicus Therapeutics Company Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.